Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$3.44M$3.44Mderived+14.1% vs Q4 2023 Net Income-$1.07M-$1.07MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$1,091,000+135.1% Operating Incomederived-$1,409,000N/M Operating Cash Flowderived$152,000N/M Free Cash Flowderived$170,000N/M Margins · derivedGross margin31.7%+16.3 pt vs Q4 2023
Operating margin-41.0%−2.8 pt vs Q4 2023
Net margin-31.0%+12.4 pt vs Q4 2023
ended Mar 31, 2024 · filed Jun 17, 2024 · 78 d after period end